DENTSPLY SIRONA
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide....
Latest News
8 hours ago · fool.com
Dentsply Sirona: 3 Key Takeaways for Long-Term InvestorsManagement reduced full-year 2026 sales guidance to approximately $3.5 billion. Wellspect Healthcare revenue grew 10% year over year to $92 million.
10 days ago · seekingalpha.com
DENTSPLY SIRONA Inc. (XRAY) Q3 2026 Earnings Call TranscriptDENTSPLY SIRONA Inc. ( XRAY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Suzanne Hatcher Daniel Scavilla - President, CEO, Interim Principal Financial Officer & Director John Fortson - Executive VP & CFO Conference Call Participants Allen Lutz - BofA Securities, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Leah Waldman Bailey - Leerink Partners LLC, Research Division Presentation Operator Good day, and thank you for standing by.
10 days ago · marketbeat.com
DENTSPLY SIRONA Q3 Earnings Call HighlightsDENTSPLY SIRONA NASDAQ: XRAY lowered its full-year earnings outlook after third-quarter sales fell across its dental businesses, as pressure from European distributor inventory reductions, the Middle East conflict and higher freight costs offset progress in parts of its U.S. operations.
11 days ago · zacks.com
XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook CutDENTSPLY SIRONA's Q3 sales decline 7.6% amid dental weakness, while Wellspect growth provides support. The company lowers its 2026 outlook.
11 days ago · zacks.com
Dentsply (XRAY) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesWhile the top- and bottom-line numbers for Dentsply (XRAY) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
11 days ago · zacks.com
Dentsply International (XRAY) Q3 Earnings and Revenues Miss EstimatesDentsply International (XRAY) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.37 per share a year ago.
13 days ago · zacks.com
DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock?DENTSPLY SIRONA faces Q3 earnings pressure from weak dental demand, tariff costs and segment challenges, while Wellspect's growth may offer some relief.
20 days ago · prnewswire.com
Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
27 days ago · globenewswire.com
Dentsply Sirona to Host Third Quarter 2026 Conference Call on November 5CHARLOTTE, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, November 5, 2026, at 4:30 p.m. EST to review its third quarter 2026 financial results. Financial earnings materials will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call.
1 month ago · globenewswire.com
Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management PortfolioMÖLNDAL, Sweden, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wellspect HealthCare today announced that the Surity™ portfolio, including the Surity™ Urinary Management System and Surity™ Female and Male External Catheters, may be covered by traditional Medicare for eligible beneficiaries when medically necessary. This milestone represents an important step in expanding access and reducing barriers to at-home management for people affected by severe urinary incontinence in the U.S.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove XRAY